MedTrace Logo

Efficacy and Safety of ChOline ALfoscerate in Patient With Mild to Moderate Alzheimer's Disease

NCT05383183 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 630

Last updated 2024-03-21

No results posted yet for this study

Summary

The purpose of this study is to determine whether combination of donepezil, a cholinesterase inhibitor, with choline alfoscerate has a more favourable clinical profile than monotherapy with donepezil alone.

Conditions

  • Alzheimer Disease

Interventions

DRUG

Choline Alfoscerate 400mg

Oral administration

DRUG

Placebo

Oral administration

Sponsors & Collaborators

  • Daewoong Bio Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-20
Primary Completion
2025-06-30
Completion
2025-12-09

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05383183 on ClinicalTrials.gov